Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.

ZENITH20 is a multicohort phase 2 study of poziotinib, a potent EGFR and HER2 exon 20 tyrosine kinase inhibitor (TKI) for the treatment of non–small-cell lung cancer (NSCLC). ZENITH20-2 targeted patients who had HER2 exon 20 insertion mutations as determined by a Clinical Laboratory Improvement Amendments–certified or equivalent sequencing test. Patients were given an oral dose of 16 mg of poziotinib daily, with allowances for changes or interruptions of treatment because of toxicity. A central independent image review committee (IIRC) evaluated the objective response rate (ORR) as a primary end point according to Response Evaluation Criteria in Solid Tumours 1.1 guidelines, with a 95% confidence interval (CI) prespecified lower bound of 17%. Disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and safety were secondary end points.

ZENITH20-2 enrolled 90 patients with advanced NSCLC and an HER2 exon 20 insertion mutation. The cohort had a median age of 60 years, was 64% female, 66% nonsmokers, 78% Caucasians, and 16% had concurrent clinically stable brain metastases at entry. Patients had a median of 2 prior therapies (range, 1-6); 98% had prior chemotherapy/platinum-based therapy, 67% had immunotherapy (including checkpoint inhibitors), and 28% had HER2 therapy.

The ORR in all 90 patients was 27.8% (95% CI, 18.9%-38.2%) and was 35.1% (95% CI, 24.4%-47.1%) in 74 patients who were evaluated by the IIRC. The DCR was 70%, the median PFS was 5.5 months (range, 0.03-13.1+ months), and the median DOR was 5.1 months (range, 1-12.3+ months, with 3 patients continuing treatment). Most subgroups showed a response to poziotinib; 31 patients with ≥3 treatments had an ORR of 38.7%, and 14 patients with central nervous system metastasis had an ORR of 28.6%. Rash (30%), diarrhea (26%), and mucosal inflammation (14%) were the most common adverse events of grade ≥3.

The ZENITH20-2 phase 2 clinical trial exceeded the designated 95% CI lower bound threshold of 17% for the ORR primary end point. The authors noted that the promising responses and manageable safety profile were typical of second-generation TKIs. Further studies will focus on alternative dosing strategies.

Reference
Socinski MA, et al. ESMO 2020. Abstract LBA60.

Related Items
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: